ARTICLE | Financial News
Clover raises RMB62.8M in series A
December 15, 2017 8:42 PM UTC
On Dec. 14, Clover Biopharmaceuticals Inc. (Chengdu, China) raised RMB62.8 million ($9.5 million) in a series A round led by new investor Tianhe Life Sciences Venture Fund.
Clover is developing covalently trimerized fusion proteins using its Timer-Tag technology to target pathways that depend on the formation of trimers to initiate downstream signaling, such as TNF superfamily proteins and enveloped RNA virus antigens. ...
BCIQ Company Profiles